On January 2nd, AstraZeneca and Sanofi jointly announced the long-acting monoclonal antibody Le Weichu& Reg; Nirsevimab has been officially approved for marketing by the National Medical Products Administration of China for the prevention of lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in newborns and infants. This medication is suitable for newborns and infants who are about to enter or are born during the first RSV infection season. Nisevizumab is expected to be launched in China during the RSV infection season of 2024-2025. AstraZeneca stated that Nisevizumab is the first officially approved respiratory syncytial virus infection prevention measure for newborns and infants in China.